Page last updated: 2024-10-15

tetrahydroneopterin

Cross-References

ID SourceID
PubMed CID135418307
CHEBI ID173817
MeSH IDM0080727

Synonyms (10)

Synonym
CHEBI:173817
25976-00-5
2-amino-6-(1,2,3-trihydroxypropyl)-5,6,7,8-tetrahydro-3h-pteridin-4-one
tetrahydroneopterin
2-amino-5,6,7,8-tetrahydro-6-(1,2,3-trihydroxypropyl)-4(1h)-pteridinone
tetrahydro-d-monapterin
5,6,7,8-tetrahydroneopterin
nph4
1-(2-amino-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)-1,2,3-propanetriol
DTXSID20948874

Bioavailability

ExcerptReference
"Conditions associated with impaired nitric oxide (NO) activity and accelerated atherosclerosis have been shown to be associated with a reduced bioavailability of tetrahydrobiopterin (BH4)."( Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase.
Brockhoff, C; Heitzer, T; Henne, S; Mayer, B; Meinertz, T; Mollnau, H; Münzel, T; Warnholtz, A, 2000
)
" Reduced nitric oxide bioavailability by interaction with reactive oxygen species is implicated in endothelial dysfunction (ED)."( (6R)-5,6,7,8-tetrahydro-L-biopterin and its stereoisomer prevent ischemia reperfusion injury in human forearm.
Casas, JP; Harris, J; Heales, S; Hingorani, AD; MacAllister, RJ; Mayahi, L; Owen, D, 2007
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
biopterins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.55)18.7374
1990's14 (63.64)18.2507
2000's5 (22.73)29.6817
2010's1 (4.55)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.55%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]